Due to its quick and intuitive base sequence design, cheap materials, easy preparation procedure, and low production cost, the creation of nucleic acid pharmaceuticals would drastically reduce the drug development cycle and enable the possibility of tailored individualized therapy regimens. Our company offers customers a complete and all-inclusive solution for drug discovery, and preclinical research services through its expert nucleic acid drug development platform.
Our Nucleic Acid Drug R&D Platform
Our company's service platform includes preclinical research services for nucleic acid drug discovery, screening and pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicity studies for pharmaceutical companies and academic research institutions. Bioinformatics, computer science, organic chemistry, RNA biology,translational research, and clinical medicine are some of the important fields in that our team of professionals expertise. Our combined solutions will assist our customers in achieving their goal of creating cutting-edge, ground-breaking nucleic acid medicines.
Our popular platform services are as follows:
Nucleic Acid Synthesis and Chemical Modification
Our platform provides nucleic acid drug synthesis and modification services. Our siRNA library not only has a rich inventory of monomers but also a huge library of monomer synthesis building blocks, which can quickly complete the synthesis of various modification monomers.
Bioactivity Screening
- Evaluation of siRNA-GALNAc binding to targeted hepatocytes.
- Evaluation of decreased target mRNA/protein levels.
- Cell phenotype evaluation and functional regulation.
- Evaluation of off-target effects.
Nucleic Acid Process Development
- We select starting materials that are easily available, less toxic, and of good quality stability.
- We develop stable, green, low-cost, and high-safety synthetic routes.
- Quality control: Up-to-date quality control system with complete technical standards
- Scale-up: End-to-end services to ensure a smooth transfer.
Nucleic Acid Drug Bioassay Capabilities
Our company offers a variety of analytical platforms for nucleic acid drug bioanalysis, including LC-MS/MS/HRMS platforms, hybridization-EIA/ECL platforms, and qPCR/ddPCR platforms.
| PK/TK Analysis | H-ELISA LC-MS/MS, H-ECL, RT-qPCR, qPCR, and ddPCR. |
| ADA Analysis | - Total ADA.
- MSD.
- Nab analysis: CLBA or cell-based assay
|
| PD or TOX-Related Cytokines and Biomarkers | - Singleplex.
- Multiplex (Luminex, MSD, FACS CBA).
- FACS.
|
Nucleic Acid Drug Pharmacological Evaluation Capabilities
- Comparison of different drug delivery modes.
- Correlation analysis of nucleic acid drug pharmacology, target mRNA/protein degradation and drug PK.
- Correlation analysis of dendritic polymer LNP.
- Correlation analysis of Luc mRNA and intratumoral.
- Correlation analysis of CNP-generated exosomes.
Nucleic Acid Drug Pharmacokinetic Study Capabilities
The building of monkey models and related research has become popular because of the advancement of nucleic acid medications and gene therapy. The advantages of Our company's ultrasound-guided liver puncture platform for crab-eating monkeys include little trauma, a safe and uncomplicated puncture operation, accurate alignment, and a good postoperative recovery.
The success rate of puncture and the precision of experimental results are considerably improved by the biopsy platform's ability to dynamically depict the entire process of biopsy needle insertion and extraction in real time. It may also be used to assess the preclinical PK of gene therapy medications, which offers a reliable pathological foundation for tracking and modeling the development of various liver disease models in real time.
For more information, please feel free to contact us.
Related Services
It should be noted that our service is only used for research, not for clinical use.
